Background {#Sec1}
==========

In Europe, mitral regurgitation (MR) represents the second most frequent heart valve disease after aortic valve stenosis \[[@CR1]\]. Among patients with moderate and severe MR, 30% are affected by functional MR (FMR) with high prevalence of the ischemic etiology \[[@CR2]\]. Despite clinical indication, 49% of patients with MR are denied for surgery due to advanced age, reduced ejection fraction or multiple comorbidities \[[@CR3]\] and, among them, the vast majority is represented by patients with FMR \[[@CR4]\]. In the last decade, percutaneous transcatheter procedures, simulating surgical techniques, have been developed to extend the therapeutic options for high surgical risk patients with MR. Among them, transcatheter mitral valve replacement (TMVR) represents the newest option \[[@CR5]--[@CR7]\].

Mitral valve (MV) geometry quantification is of paramount importance for the success of TMVR, and transthoracic (TTE) three-dimensional echocardiography (3DE) represents a useful tool to select the patients with the highest likelihood of uncomplicated implant \[[@CR8]\]. It has been previously reported that MV geometry may differ in ischemic and non-ischemic FMR. In patients with ischemic MR (IMR), regional wall motion abnormalities and left ventricular \[[@CR9]\] remodeling are more often associated with mitral annulus (MA) asymmetric dilatation \[[@CR10]\]. Conversely, in non-ischemic MR (nIMR) global LV remodeling leads to symmetric MA dilatation \[[@CR11]\]. Yet, MV geometry in FMR has been mainly compared to organic MR, and only few small echocardiographic studies analyzed MV geometry differentiating between IMR and nIMR \[[@CR10]--[@CR13]\]. However, none of them provided MA geometry characterization framed to pre-procedural screening for TMVR \[[@CR8]\].

The aim of this study was to asses MV geometry in patients with FMR that would potentially benefit of TMVR, focusing on the comparison of MA geometry between IMR and nIMR patients in two key moments of the cardiac cycle ---mid-systole and early-diastole.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Using the electronical database of the echocardiography laboratory of the department of cardiac, thoracic and vascular sciences of the University of Padua, 94 patients with severe FMR and complete transthoracic echocardiography performed between November 2010 and March 2018, have been retrospectively selected. Inclusion criteria were: age \> 18 years; severe FMR according to current guidelines \[[@CR14]\]; availability of good quality 3D data sets of both the left ventricle (LV) and the MV. We excluded patients with organic MR, mitral stenosis, aortic stenosis, more than moderate aortic regurgitation, or those with valve prostheses. Each patient was assigned to the IMR or nIMR subgroup according to his/her clinical history and the documentation of presence/absence of significant coronary artery diseases. The study was approved by the University of Padua Ethics Committee (protocol no. 70299).

Mitral valve analysis software package validation {#Sec4}
-------------------------------------------------

Two sub-studies were carried on to validate the software package used to quantitate MV geometry (4D Auto MVQ, GE Vingmed Ultrasound AS, Horten, Norway). First, the same operator (P.A.) performed the quantitative analysis of the MV in a blinded fashion, and after a time interval of one month form each other, using the same TTE data sets and both the new and a previously validated \[[@CR15], [@CR16]\] (4D MV Analysis; Tomtec Imaging Systems, Unterschleissheim, Germany) software packages. Second, 3D TTE and transesophageal (TEE) echocardiographic MV data sets were analyzed using the same software package for MV quantitative analysis (4D Auto MVQ, GE Vingmed Ultrasound AS, Horten, Norway) by the same operator (P.A.) in a blinded fashion, after a time interval of one week.

Echocardiography and quantitative image analysis {#Sec5}
------------------------------------------------

All transthoracic examinations were performed using a commercially available Vivid E9 system (GE Vingmed Ultrasound AS, Horten, Norway) equipped with a 4 V probe for 3DE acquisitions according to a standardized protocol. Image analysis was performed on a dedicated workstation equipped with a commercially available software package for offline analysis of 3D datasets (EchoPac 2.02). Quantitation of LV volumes and ejection fraction (LVEF) was performed using 4D Auto-LVQ software \[[@CR17]\] (GE Vingmed Ultrasound AS, Horten, Norway). Left atrium (LA) maximum volume was measured using the biplane disk summation method, at LV end-systole \[[@CR18]\]. MR severity and conventional MV geometry parameters ---antero-posterior (AP) and commissural (CC) diameters, tenting height and tenting area--- were assessed according to current recommendations \[[@CR14]\]. 3D MA analysis was performed on dedicated datasets by a single experienced observer (P.A.), using a new, commercially available, software package (4D Auto MVQ, GE Vingmed Ultrasound AS, Horten, Norway), in two moments of the cardiac cycle: early-diastole and mid-systole. Firstly, two time points were identified in the way that the selected frame of the analysis was midway among them. For mid-systolic analysis, the two time-points were early-systole (the frame after MV closure) and end-systole (the frame before MV begins to open). For early diastolic analysis, after identification of early-diastolic frame (first frame when MV start to open), the two time-points were placed 8 frames before and after the selected early-diastolic frame. The two orthogonal planes were adjusted to visualize the commissural and longitudinal view of MV (the longitudinal plane intersected the MV at the level of A2 and P2 scallops). For initialization, anatomic landmarks have to be added at the level of MA in the longitudinal view (posterior, P; anterior, A; leaflets coaptation point, Coap; and aortic valve, Ao) and commissural view (MA1 and MA2). The software package automatically created a 3D model of the MV in the selected frame which could eventually be edited manually, if needed (Fig. [1](#Fig1){ref-type="fig"}). Automatic quantitative parameters of the MV geometry were: MA 3D area; MA 2D area (projected 2D area at the level of the best fit plane); MA perimeter; MA AP diameter, as the distance between the two landmarks A and P; MA anterolateral-posteromedial diameter (ALPM), as the longest diameter of MA perpendicular to AP diameter; sphericity index (as the ratio between AP and ALPM diameters); MA CC diameter, as the distance between the two commissure; MA inter-trigonal distance, measured between the two automatically identified trigons; MA height, as the distance between the lowest and the highest points of MA; the non-planimetry angle, that assesses the saddle shape of MA; mitral-aortic angle, as the angle between the aortic valve and the MA (along the AP direction) planes; anterior and posterior leaflets area and length, MV tenting height, tenting area and tenting volume.Fig. 1Mitral annulus parameters automatically analyzed at mid-systolic frame. Legend: Panel **a** 3D mitral annulus area, **b** mitral annulus area at the best fit plane, **c** Inter-trigonal distance, **d** Aorto-Mitral angle

Statistical analysis {#Sec6}
--------------------

The normal distribution of the variables was checked using the Kolmogorov-Smirnov test. Continuous data were presented as mean ± standard deviation (SD) or Median (25°-75°) and categorical variables as absolute numbers and percentages, as appropriate. In the validation study, we used Pearson or Spearman correlation to test the relationships between TTE mid-systolic MA parameters, measured using the two software packages, and mid-systolic and early-diastolic parameters obtained from TTE and TEE data sets in the same patient. In addition, Bland--Altman plots were used to assess the mean difference and the limits of agreement between them. Paired t test or Wilcoxon rank test were used, as appropriate, for comparing the MV dimension obtained by TTE and TEE data set in the same patient.

Variables were compared between IMR and nIMR patients using the unpaired t or the Mann-Whitney tests, as appropriate. Chi-square was used to compare the categorical variables. A paired t test or Wilcoxon signed rank test was used to compare systolic and diastolic dimensions within the same subgroups, as appropriate. Percentage change of the systo-diastolic measurements was also calculated.

Data analyses was performed using SPSS version 20.0 (SPSS, Inc., Chicago, IL) and GraphPad Prism V 7 (GraphPad Software, La Jolla, NY). Differences among variables were considered significant at *p* value \< 0.05.

Results {#Sec7}
=======

Validation study {#Sec8}
----------------

The TTE validation cohort included 30 patients (15 with IMR; 22 men; mean age 64 ± 2 year) with good image quality. The temporal resolution of the 3D dataset for MV quantification was 35 ± 3 volumes per second (vps). Close correlations and good agreements were found between the measurements obtained with the two software packages (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 2Comparisons of mitral annulus diameter measured by GE and TomTec software using Pearson correlation (top) and Bland--Altman (bottom) analysesFig. 3Comparisons of mitral annulus area and perimeter measured by GE and TomTec software using Pearson correlation (top) and Bland--Altman (bottom) analyses

The TEE validation cohort included 15 patients (8 with IMR; 14 men; mean age 63 ± 15 year). As expected, both image quality (excellent quality in 75% versus 25%, respectively, *p* = 0.009) and temporal resolution (34 ± 15 vps versus 29 ± 10 vps, respectively, *p* \< 0.05) were higher for TEE than TTE data sets. The mean time lapse between TTE and TEE data set acquisitions was 1(0--6) day.

Measurements obtained from TEE data sets resulted in slightly larger area, perimeter and AP diameter (Table [1](#Tab1){ref-type="table"}). However, there was a close correlation between the two techniques and the differences were not clinically relevant. Among linear dimension, ALPM, commissural diameter and diastolic inter-trigonal distance are the most similar in TEE and TTE data sets, while tenting area, tenting volume and non-planar showed the largest differences (Table [1](#Tab1){ref-type="table"}).Table 1Comparison of mitral annulus parameter among transthoracic and transoesophageal data setsTransthoracic *N* = 15Transoesophageal *N* = 15*pr*Diastolic dimension Annulus area (3D) (cm^2^)11.5 ± 3.112.4 ± 3.20.0310.879\*\* Annulus best fit plane (cm^2^)10.6 ± 3.011.7 ± 3.10.0160.869\*\* Annulus perimeter (cm)12.1 ± 1.712.6 ± 1.60.0360.883\*\* AP diameter (cm)3.5 ± 0.53.8 ± 0.50.0120.799\*\* ALPM diameter (cm)3.7 ± 0.53.8 ± 0.50.3420.840\*\* Commissural diameter (cm)3.7 ± 0.43.8 ± 0.50.2310.777\*\* Itertrigonal distance (cm)2.8 ± 0.33.0 ± 0.40.0940.715\*\* Sphericity index0.9 ± 0.11.0 ± 0.10.1500.157 Annulus height (mm)7.3 ± 1.76.8 ± 1.60.3430.559\* Non planar angle156 ± 13152 ± 110.3140.474 Mitro-aortic angle131 ± 8125 ± 100.0390.418Systolic dimension Annulus area (3D) (cm^2^)10.2 ± 2.611.0 ± 2.60.0060.936\*\* Annulus best fit plane (cm^2^)9.3 ± 2.510.2 ± 2.50.0010.959\*\* Annulus perimeter (cm)11.4 ± 1.511.8 ± 1.40.0100.943\*\* AP diameter (cm)3.2 ± 0.43.4 ± 0.60.0020.624\* ^ρ^ ALPM diameter (cm)3.6 ± 0.53.6 ± 0.40.3290.857\*\* Commissural diameter (cm)3.5 ± 0.43.6 ± 0.40.1510.889\*\* Itertrigonal distance (cm)2.6 ± 0.43.0 ± 0.40.0000.830\*\* Sphericity index0.9 ± 0.10.9 ± 0.10.0620.321^ρ^ Annulus height (mm)7.0 ± 1.37.0 ± 1.40.9100.300 Non planar angle (°)153 ± 10153 ± 90.8930.240 Aorto-mitral angle (°)139 ± 10129 ± 80.0050.367 Tenting height (mm)10.3 ± 2.07.2 ± 3.60.02- 0.108 Tenting area (cm^2^)2.3 ± 0.62.3 ± 0.70.9340.542\* Tenting volume (mL)4.2 ± 1.34.1 ± 1.50.7420.747\*\*Data are expressed as Mean ± Standard Deviation*Abbreviations*: *ALPM* anterolateral-posteromedial, *AP* antero-posterior diameter\* for correlation with *p* \< 0.05; \*\* for correlation with *p* \< 0.001; ^ρ^ evaluated with Sperman's correlation

Comparison of mitral annulus geometry between ischemic and non-ischemic mitral regurgitation {#Sec9}
--------------------------------------------------------------------------------------------

We enrolled 94 patients, 41 (43,6%) with IMR and 53 (56,4%) with nIMR. Patients with IMR were more frequently male and had a higher incidence of hypertension, diabetes and dyslipidemia (Table [2](#Tab2){ref-type="table"}). The severity of MR was comparable between the two groups (Table [3](#Tab3){ref-type="table"}). Although patients in both groups showed severe LV dilatation and dysfunction, patients with IMR had a higher LVEF (31 (26--38)% versus 28 (22--32)%, *p* = 0.030) and LV wall motion score index (2.1 ± 0.3 versus 1.9 ± 0.6, *p* = 0.021) (Table [3](#Tab3){ref-type="table"}).Table 2Demographics and clinical characteristicsIschemic mitral regurgitation *N* = 41Non ischemic mitral regurgitation *N* = 53*p*Age (years)69 (63--75)64 (55--72)0.081Men (%)*35 (85)35 (66)0.033*Body surface area (m^2^)1.8 (1.7--1.9)1.9 (1.7--2.0)0.374Heart rate (bpm)71 (59--85)75 (65--86)0.237Systolic blood pressure (mmHg)110 (100--120)100 (95--115)0.340Diastolic blood pressure(mmHg)65 (60--71)65 (60--70)0.233Hypertension*32 (80%)25 (48.1%)0.002*Diabetes*15 (37.5%)8 (15.4%)0.015*Dyslipidemia*30 (75%)22 (42.3%)0.002*Smokers23 (57.5%)24 (46.2%)0.280Resynchronization therapy8 (20%)17 (32.7%)0.175Data are expressed as Median (25°-75°) or Number (%). Italicized values highlight statistically significant differencesTable 3Echocardiography characteristicsIschemic mitral regurgitation *N* = 41Non ischemic mitral regurgitation *N* = 53*p*MR Vena contracta (mm)7 (6--8)7 (6--8)0.658MR PISA radius (mm)7 (6--8)8 (7--9)0.138MR EROA (mm2)2 (2--3)2.1(2--3)0.421MR R Vol (mL)38 (28--58)38.5 (29--47.7)0.803sPAP47 (35--56)44 (35--49)0.211TR severityTrivial 6 (11.3%)Trivial 6 (15.4%)0.753Mild 29 (54.7%)Mild 20 (51.3%)Moderate11 (20.8%)Moderate10 (25.6%)Severe 7 (13.2%)Severe3 (7.7%)AR severityNone 25 (49%)None 25 (65%)0.437Trivial 13 (25%)Trivial 6 (15%)Mild 12 (23.5%)Mild 9 (22.5%)Moderate 1 (2%)Moderate 0 (0%)LV EDV (ml/m^2^)134 (114--153)143 (116--178)0.078LV ESV (mL/m^2^)96 (68--109)105 (78--135)0.075Ejection Fraction (%)*31 (26--38)28 (22--32)0.030*Indexed LA volume (mL/m2)*60 (51--68)70 (53--91)0.031*Data are expressed as Median (25°-75°) or Number (%)*Abbreviations*: *AR* aortic regurgitation, *EROA* effective regurgitant orifice area, *LA* left atrial, *LV EDV* left ventricular end-diastolic volume, *LV ESV* left ventricular end-systolic volume, *MR* mitral regurgitation, *PISA* proximal isovelocity surface area, *R Vol* regurgitant volume, *sPAP* systolic pulmonary artery pressure, *TR* tricuspid regurgitation. Italicized values highlight statistically significant differences

Temporal resolution of the 3D dataset dedicated for MV quantification was higher in IMR than in nIMR patients (33 ± 14 vps versus 40 ± 16 vps, *p* = 0.023). All data sets had enough good quality for the quantitative analysis. The image quality was graded excellent in 47 patients (50%), good in 32 (34%), and fair in 15 (16%) and it was comparable between IMR and nIMR patients (*p* = 0.634).

Using conventional two-dimensional echocardiography MV geometry parameters, patients with nIMR showed larger AP diameter both in diastole (41 ± 7 mm in nIMR versus 38 ± 6 mm in IMR, *p* = 0.029) and in systole (37 ± 6 mm in nIMR versus 34 ± 4 mm in IMR, *p* = 0.024). Conversely, CC diameter (43 ± 8 mm in nIMR versus 39 ± 9 mm in IMR, *p* = 0.088), tenting height (9 ± 3 mm in nIMR versus 8.5 ± 3 mm in IMR, *p* = 0.180) and tenting area (1.9 ± 0.7 cm^2^ in nIMR versus 1.7 ± 0.6 cm^2^ in IMR, *p* = 0.189) were similar between the two groups.

At 3DE analysis, both subgroups had similar diastolic geometry of MA, even though all MA dimensions were slightly larger in nIMR. nIMR patients showed larger mid-systolic 3D area and perimeter of the MA with longer leaflets. However, the area of the annulus at the best fit plane, and all diameters (AP, CC, ALPM diameter and trans-trigonal distance) did not differ between IMR and nIMR patients. Tenting height and area did not differ between IMR and nIMR patients, whereas tenting volume, annulus height and aorto-mitral angle were larger in nIMR patients (Table [4](#Tab4){ref-type="table"}).Table 4Three-dimensional mitral valve dimensionIschemic mitral regurgitation *N* = 41Non ischemic mitral regurgitation *N* = 53*p*Diastolic dimension Annulus area (3D) (cm^2^)10.7 ± 2.5^a^11.6 ± 2.7^a^0.124 Annulus best fit plane (cm^2^)9.9 ± 2.3^a^10.7 ± 2.5^a^0.135 Annulus perimeter (cm)11.7 ± 1.4^a^12.2 ± 1.4^a^0.111 AP diameter (cm)3.3 ± 0.4^a^3.5 ± 0.5^a^0.072 ALPM diameter (cm)3.6 ± 0.4^a^3.8 ± 0.5^a^0.129 Commissural diameter(cm)3.6 ± 0.43.7 ± 0.40.300 Itertrigonal distance (cm)2.7 ± 0.4^a^2.8 ± 0.3^a^0.374 Annulus height (mm)6.3 ± 1.7^a^6.8 ± 1.7^a^0.144 Sphericity index0.9 ± 0.1^a^0.9 ± 0.1^a^0.963 Non planar angle (°)156 ± 11^a^153 ± 10^a^0.232 Anterior leaflet area (cm^2^)7.5 ± 1.6^a^8.0 ± 1.6^a^0.142 Posterior leaflet area (cm^2^)7.2 ± 2.3^a^7.5 ± 2.1^a^0.413 Anterior leaflet length (cm)2.9 ± 0.43.3 ± 0.9^a^0.102 Posterior leaflet length (cm)1.6 ± 0.4^a^1.7 ± 0.6^a^0.319 Aorto-mitral angle (°)131 ± 9^a^135 ± 11^a^0.115Systolic dimension Annulus area (3D) (cm^2^)*9.8 ± 2.310.8 ± 2.70.046* Annulus best fit plane (cm^2^)9 ± 2.19.9 ± 2.50.063 Annulus perimeter (cm)*11.2 ± 1.311.8 ± 1.50.048* AP diameter (cm)3.1 ± 0.43.2 ± 0.50.063 ALPM diameter (cm)3.5 ± 0.43.7 ± 0.50.065 Commissural diameter(cm)3.5 ± 0.43.7 ± 0.40.130 Itertrigonal distance (cm)2.5 ± 0.32.7 ± 0.30.051 Annulus height (mm)*6.7 ± 1.67.5 ± 1.90.047* Sphericity index0.9 ± 0.080.9 ± 0.10.598 Non planar angle (°)153 ± 11150 ± 100.268 Anterior leaflet area (cm^2^)*6.5 ± 1.67.4 ± 1.70.006* Posterior leaflet area (cm^2^)*5.7 ± 1.76.5 ± 1.90.049* Anterior leaflet length (cm)*2.8 ± 0.63 ± 0.40.022* Posterior leaflet length (cm)*1.3 ± 0.41.5 ± 0.80.022* Aorto-mitral angle (°)*135 ± 10141 ± 110.011* Tenting height (mm)9.3 ± 2.610.3 ± 2.80.082 Tenting area (cm^2^)2.2 ± 0.72.4 ± 0.80.141 Tenting volume (mL)*4 ± 1.74.7 ± 1.70.047*Data are expressed as Mean ± Standard Deviation*Abbreviations*: *ALPM* anterolateral-posteromedial, *AP* antero.posterior diameterItalicized values highlight statistically significant differences^a^Statistical difference vs systolic dimension

Mitral annulus dynamics {#Sec10}
-----------------------

In both groups, MA significantly reduced its dimensions in systole (except for the CC diameter) with similar percentage change of the measurement in both groups (*p* \> 0.05) (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). During systole, the MA mitral-aortic angle flattens, while the non-planarity angle becomes more acute.Table 5Fractional changes of the mitral annulus parameters between diastole and systoleIschemic mitral regurgitation *N* = 41Non ischemic mitral regurgitation *N* = 53*p*MA area (3D) fraction (%)-6 (-11.7 --- -1.8)-4.3 ( -9.8 --- -1.3)\> 0.05MA best fit plane fraction (%)-6.3 (-13 --- -4)-6.7 (-11.4 --- -1.8)\> 0.05MA perimeter fraction (%)-3.2 (-5.8 --- -0.4)-2.1 (-4.6 --- -0.8)\> 0.05AP diameter fraction (%)-7.4 (-11.4 --- -2.4)-5.9 (-11.2 --- -1.3)\> 0.05ALPM diameter fraction (%)-2.9 (-6.9 --- 0.0)0.0 (-7.3 --- 0.0)\> 0.05CC diameter fraction (%)-2.6 (-5.5 --- 2.9)0.0 (-4.7 --- 2.7)\> 0.05TT distance fraction (%)-4.8 (-12.4 --- 0.0)-3.1 (-10 --- 3.8)\> 0.05Non planar angle fraction (%)-2 (-6.3 --- 2.5)-2.4 (-5.6 --- 2)\> 0.05Aorto-mitral angle fraction (%)3.7 (-2.5 --- 8.4)3.4 (0--8.4)\> 0.05Data are expressed as Median (25°-75°)*Abbreviations*: *ALPM* anterolateral-posteromedial, *AP* antero-posterior diameter, *CC* commissural, *MA* mitral annulus, *TT*, trans-trigonal

Discussion {#Sec11}
==========

In the present study, we used 3D TTE to compare MA geometry in patients with severe ischemic and non-ischemic FMR, who are potential candidates for TMVR.

The main findings of our study were in patients with FMR: i, diastolic MA geometry is similar in both nIMR and IMR patients; ii, systolic MV geometry significantly differs between the groups.

Validation study {#Sec12}
----------------

Multimodality imaging represents the gold standard for planning transcatheter mitral valve procedures, TEE and multi-slice computed tomography (MSCT) playing the major role \[[@CR19]\]. Due to longer survival of patients with chronic heart diseases and progressive aging of the general population, the number of patients who could benefit of TMVR is likely to increase, and 3DTTE will be of paramount importance as a screening tool for the analysis of MV geometry. Previous clinical studies assessing MA geometry used 3DTEE data sets \[[@CR20], [@CR21]\] to obtain adequate spatial and temporal resolution for quantitative analysis of the MV. However, the progressive improvement of 3DE technology allows to obtain better and better quality 3DE data sets with TTE, too. Moreover, feasibility and cost/effectiveness considerations suggest that TTE approach would be better suited to screen potential candidates to TMVR. Accordingly, we decided to explore the use of 3DTTE data sets perform quantitative analysis of the MV in patients with FMR. In our patients, MA dimensions obtained from TTE datasets were similar to those obtained with the 3D TEE approach in the validation study.

Comparison of mitral annulus dimension between ischemic and non-ischemic mitral regurgitation {#Sec13}
---------------------------------------------------------------------------------------------

We focused our study on patients with FMR because they represent the main potential target of new TMVR. The few previous studies that analyzed the possible differences between IMR and nIMR \[[@CR10]--[@CR13]\] included a limited number of patients and were focused only on MA size (annulus area and diameters), without any information about the MV geometry (MA area at the best fit plane, mitro-aortic angle, length of the anterior leaflet) which are crucial to select patients for TMVR \[[@CR19]\].

In this study, we reported all MV anatomical and geometrical features that should be assessed before TMVR \[[@CR8], [@CR22]\] and demonstrated that patients with severe IMR and nIMR have similar, symmetrical, diastolic (maximal) MA dimension. The 3D MA area obtained from our patients were comparable with the maximum MA surface area reported by Veronesi et al. \[[@CR12]\] in a smaller group of patients using TTE 3DE datasets. Our results are also in agreement with those reported by Daimon et al. \[[@CR10]\] who showed that diastolic MA diameters did not differ among IMR and nIMR. However, the actual MA sizes in our patients were slightly larger than in their cohorts. This finding could be partially explained by the different time point selected for the analysis (mid-diastolic phase, compared to early-diastole in our study).

While in our study mid-systolic 3D annulus area and perimeter are significantly larger in patients with nIMR, MA area at the best fit plane and MA diameter were similar. It has been suggested that the projected 3D MA area at the level of the best fit plane is the most reliable parameter of MA geometry to be used for planning TMVR compared to the saddle-shaped 3D area \[[@CR22]\]. Though, our MA area at the best fit plane resulted smaller than the mean projected MA area measured in a recent MSCT study \[[@CR23]\] on 32 patients with FMR of different etiologies and severity, it is already known that 3DE can underestimate measurement compared with MSCT due to its suboptimal lateral resolution in the coronal plane \[[@CR24]\].

A new D-shaped MA segmentation developed by Blanke et al. \[[@CR25]\], with the truncation of anterior saddle horn at the level of inter-trigonal line, has been used to select candidates to Tiara \[[@CR5]\], Tendyne \[[@CR7]\] and Intrepid \[[@CR6]\] valve implants. This method was also recently applied by Mak et al. \[[@CR26]\] using 3D TEE with comparable results, but it is unclear at this early stage of TMVR experience whether this is the best parameter to size the prosthesis for TMVR interventions \[[@CR27]\].

Left ventricular out flow tract (LVOT) obstruction is a possible complication related to TMVR that can be predicted during procedure planning because it is related to the design of the prosthesis and patient anatomy (interventricular septal dimension, LV size, aorto-mitral angle, anterior leaflet length). 3DE allows the measurement of both the aorto-mitral angle (the angle between the aortic valve and the MA along the AP direction) and anterior leaflet length. None of the previous MSCT nor the 3DE studies reported these parameters in patients considered for TMVR. In our study we found that nIMR group presented significantly wider aorto-mitral angle that balance the potential higher risk of LVOT obstruction due to longer and larger anterior leaflets in these patients.

Mitral annulus dynamics {#Sec14}
-----------------------

MA is dynamic structure characterized by contraction and expansion phase during cardiac cycle \[[@CR12], [@CR28]\]. These changes, although less pronounced than in normal subjects, have been reported also in patients with IMR \[[@CR20], [@CR29]\] and nIMR \[[@CR12]\]. We found that in patients with severe FMR, MA is significantly smaller in mid-systole compared to early diastolic phase. This findings underline the necessity of a multiphasic MA assessment to select patients for TMVR \[[@CR8]\], but the few investigations that analyzed MA dimension in moderate or severe FMR (potentially candidates for TMVR), reported only the measurement in one phase of the cardiac cycle \[[@CR12], [@CR13]\].

Implications for trans-catheter mitral valve selection {#Sec15}
------------------------------------------------------

TMVR represents a promising option for patients with severe FMR, and assessment of MA dimension and geometry is of paramount importance to size the device and also to plan future development of new prostheses. We found that, patients with IMR and nIMR have similar MA geometry, supporting the concept that there is no need of different prosthesis sizing according to etiology of the FMR. However, we found that nIMR patients had significantly larger and longer anterior mitral leaflet, that could increase the risk of LVOT obstruction. Therefore, for nIMR patients it could be more appropriate to select a device that has an anterior hook to fix the anterior leaflet of the native MV. On the other hand, nIMR patients showed a wider aorto-mitral angle that could counterbalance the higher risk of LVOT obstruction carried by longer anterior leaflet. Probably, this sub-group of patients would be eligible also for devices that have larger protrusion or flaring into LV.

The significant change of MA during the cardiac cycle, also preserved in patients with severe FMR, stresses the need to evaluate accurately the smallest MA dimension in order to reduce the risk of excessive stress of the prosthesis frame by MA.

Study limitations {#Sec16}
-----------------

We acknowledge several limitations of our study. First, to obtain all the measurements needed to plan TMVR from 3DE data sets, we used a new MV software package that was not previously validated. To overcome this limitation, we compared the measurements obtained with the new software package with those obtained from the same data sets using a validated software \[[@CR16]\] with a close correlations and good agreement. However, we did not compare our measurement with MSCT, which represents the current gold standard to select patients for TMVR.

Secondly, currently available 3DE software packages allow MV dynamic analysis only during the systolic phase of the cardiac cycle. While mid-systole could be defined by the operator according to MV opening and closure or automatically by the software (as mid-way between R and T waves on the ECG tracing), early-diastole has to be manually identified by the operator with an increased possibility of errors. Current literature reports contradicting data about the moment when MA reaches its maximum and minimum sizes, however the importance of definition of maximum MA dimension is of paramount importance for accurate device's sizing and emphasizes the need of multiphasic annular measurement.

Conclusion {#Sec17}
==========

The reported MA geometry in a relatively large group of patients with severe FMR, potentially candidates for TMVR, represents useful information for transcatheter MV prosthesis design and patient selection. Patients with ischemic and non-ischemic aetiologies of FMR have similar maximum dimensions, yet systolic differences between the two groups should be taken into account to tailor prosthesis's selection.

3DE

:   Three-dimensional echocardiography

ALPM

:   Anterolateral-posteromedial

AP

:   Antero-posterior

CC

:   Commissural

FMR

:   Functional mitral regurgitation

IMR

:   Ischemic MR

LA

:   Left atrium

LV

:   Left ventricle/ventricular

LVEF

:   Ejection fraction

LVOT

:   Left ventricular outflow tract

MA

:   Mitral annulus

MR

:   Mitral regurgitation

MSCT

:   Multi-slice computed tomography

MV

:   Mitral valve

nIMR

:   Non-ischemic mitral regurgitation

TMVR

:   Transcatheter mitral valve replacement

TEE

:   Transesophageal echocardiography

TTE

:   Transthoracic echocardiography

VPS

:   Volumes per second
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